Tim Ferng, MD
Assistant Professor
Medicine
School of Medicine

Education & Training

Show all (4) Hide

• Hematology and Oncology Fellowship University of California San Francisco 07/2019
• Internal Medicine Residency New York Presbyterian - Weill Cornell Medical Center 06/2013
• MD Doctor of Medicine Wayne State University School of Medicine 06/2010
• BS Cell and Molecular Biology University of Michigan 05/2006

Publications (3)

Top publication keywords:
Drug Evaluation, PreclinicalGuanine Nucleotide Exchange FactorsrhoA GTP-Binding ProteinSmall Molecule LibrariesLeukemia, Myeloid, AcuteTumor Microenvironmentras ProteinsAmidesGrowth InhibitorsPyrimidinesDrug Resistance, NeoplasmClonal EvolutionProtein Kinase Inhibitorsfms-Like Tyrosine Kinase 3Cell Line, Tumor

• The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms.
  Molecular cancer therapeutics 2022 Ferng TT, Terada D, Ando M, Tarver TC, Chaudhary F, Lin KC, Logan AC, Smith CC
• Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.
  Cancer discovery 2019 McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJD, Eastburn DJ, Pellegrino M, Durruthy-Durruthy R, Watt CD, Asthana S, Lasater EA, DeFilippis R, Peretz CAC, McGary LHF, Deihimi S, Logan AC, …
• High-throughput screening for small-molecule inhibitors of LARG-stimulated RhoA nucleotide binding via a novel fluorescence polarization assay.
  Journal of biomolecular screening 2009 Evelyn CR, Ferng T, Rojas RJ, Larsen MJ, Sondek J, Neubig RR